Miach Orthopaedics is a medical device company specializing in developing bio-engineered surgical implants for connective tissue restoration. Founded in 2016 by Martha Murray, MD, and Braden Fleming, Ph.D., the company is based in Westborough, Massachusetts. Known for its flagship product, the Bridge-Enhanced ACL Restoration (BEAR®) Implant, Miach Orthopaedics has aimed to revolutionize anterior cruciate ligament (ACL) repair by promoting natural healing. Over the years, Miach has successfully secured funding to support its growth, indicating significant interest and support from investors and stakeholders within the orthopaedics industry.
September 2024: Miach Orthopaedics announced its participation in the Orthopaedic Summit Evolving Techniques Conference 2024. The event featured scientific presentations highlighting the BEAR Implant's capabilities, surgical techniques, and patient selection criteria. An interim analysis of the Bridge Registry Study was presented, offering insights into real-world patient outcomes.
April 2024: The company raised $20 million in a Series B extension financing round. Major League Soccer Players Association (MLSPA), SV Health Investors, and Aperture Venture Partners were among the contributors. This funding is earmarked for commercial expansion and clinical initiatives, such as the Bridge Registry.
January 2023: Miach Orthopaedics secured $40 million in financing to facilitate the U.S. rollout of the BEAR Implant. This move has bolstered the company's capacity to meet increasing demand among athletes and the general population for innovative treatment of ACL injuries.
| Attribute | Information |
|---|---|
| Founding Date | 2016 |
| Headquarters | Westborough, Massachusetts |
| Founders | Martha Murray, MD; Braden Fleming, Ph.D. |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | MLSPA, SV Health Investors, Aperture Venture Partners, NFLPA, Amzak Health |
| Industry | Orthopedic Medical Devices |
| Number of Employees | Not publicly disclosed |
Miach Orthopaedics traces its roots to groundbreaking research conducted at the Boston Children’s Hospital by Dr. Martha Murray. The research, primarily funded by Boston Children’s Hospital, the National Institutes of Health, and the NFL Players Association, led to the development of the BEAR Implant. The implant represented a significant shift in orthopedic surgery by enabling natural restoration of torn ACLs, as opposed to traditional reconstructive methods. With a deeply rooted mission to advance ACL repair techniques, Miach Orthopaedics was officially founded in 2016.
Miach Orthopaedics operates on a business model centered around innovation in surgical implants for ligament restoration. Its BEAR Implant has garnered attention due to its unique ability to use the patient’s own blood to facilitate ACL healing.
2016: Established in Westborough, MA, beginning the journey to redefine ACL repair.
2020: Achieved De Novo FDA approval for the BEAR Implant, marking a regulatory milestone enabling wider clinical application.
2021: Launched the BEAR Implant in select U.S. markets with considerable interest from both surgeons and patients.
2023-2024: Secured cumulative funding rounds amounting to $60 million, driven by major sports associations and investment firms, indicating substantial confidence in its innovative solutions.
Presently, Miach Orthopaedics focuses on expanding the commercial availability and application of its BEAR Implant. The company targets orthopaedic professionals and healthcare systems that address sports injuries, particularly ACL tears. Competitive advantages include the BEAR Implant's minimally invasive nature and its promotion of natural ACL healing—factors contributing to its rising adoption rates among practitioners.
Miach Orthopaedics stands as a pivotal player in the orthopaedics sector, deeply influencing ACL surgery practices with its groundbreaking BEAR Implant. With continued financial backing and strategic expansions, the company is poised to maintain its momentum and further entrench its influence within sports medicine. Looking ahead, Miach Orthopaedics could significantly impact how connective tissue injuries are treated across the healthcare spectrum.